… Therefore, advanced unresectable bone sarcomas remain orphan … tyrosine-kinase receptors
(TKRs) has emerged as a promising strategy to improve the results of systemic treatment. …

… role of tyrosine kinase inhibitors (TKIs) in patients with recurrent or … that inhibit these receptor
tyrosine kinases (11,12). … in the treatment of patients with locally advanced, unresectable, or …

… immune checkpoint inhibitors and tyrosine kinase inhibitors were … in unresectable or
incompletely resected bone sarcoma – … palliation in unresectable or recurrent bone sarcomas of …

… , was originally identified as a transforming gene in chronic myelogenous leukemia. It is the
… soft tissue sarcoma (n = 9), Ewing sarcoma (n = 3), and osteosarcoma (n = 4) patients treated …

… drugs which therapeutically block tyrosine kinase receptors or their … treatment of osteosarcoma
has presented a plateau. Outcomes of patients with recurrent or metastatic bone sarcoma …

… -ABL fusion tyrosine kinase that defines chronic myeloid leukemia [18… ALCL and 14 patients
with inoperable/metastatic IMT [27]. … for bone sarcomas. Examples of ongoing studies of RTK …

… A large number of tyrosine kinase inhibitors (TKIs) have … as a treatment option for
recurrent/metastatic Ewing sarcoma, … of IGF1 receptor (IGF1R) is observed in Ewing sarcoma cells …

… A number of receptor tyrosine kinase growth factors have … treatment agent in patients with
relapsed and unresectable OS, … SRC kinase inhibitor, in patients with recurrent osteosarcoma …

… bone sarcoma patients. One phase II trial that was designed to evaluate the safety and anti-tumor
efficacy of pazopanib in patients with unresectable… Treatment-specific frequent adverse …

… anlotinib in the treatment of recurrent or metastatic primary malignant bone tumors. Among
… of anlotinib in the treatment of patients with unresectable or metastatic bone sarcoma [99]. A …